Scotiabank Maintains Outperform on Vertex Pharmaceuticals (VRTX) Feb 13, 2026

VRTX analyst rating: Scotiabank maintained an Outperform on Vertex Pharmaceuticals Incorporated (VRTX) on February 13, 2026, and raised its price target to $558. The same day Morgan Stanley kept an Overweight and nudged its target to $570. Both firms left ratings intact, signaling ongoing confidence in Vertex’s franchise and pipeline. These moves update investor expectations about upside and valuation on the same trading day.

VRTX analyst rating: Scotiabank maintains Outperform and raises target to $558

On February 13, 2026 at 10:28 AM, Scotiabank maintained an Outperform rating on Vertex and raised its price target to $558 from $495. The firm framed the change around updated revenue models and longer-term franchise strength. The report noted a -0.74% intraday move equal to -$3.68 since the notice. Read the Scotiabank note on The Fly for full details source.

VRTX analyst rating: Morgan Stanley maintains Overweight and lifts target to $570

On February 13, 2026 at 11:08 AM, Morgan Stanley maintained an Overweight rating and raised its price target to $570 from $564. The move was modest but keeps Morgan Stanley among the more bullish major houses. The note reported a -0.71% change equal to -$3.52 since publication. See Morgan Stanley’s update on The Fly for the analyst rationale source.

VRTX analyst rating: What maintained ratings mean for investors

A maintained rating means analysts see no change to their core view. Both firms expect Vertex’s growth drivers to justify current conviction. Investors should read the reports and weigh upgraded targets against risks like trial outcomes and pricing pressure. Maintained coverage with higher targets often signals model tweaks, not a shift in conviction.

VRTX analyst rating: Price targets, market cap, and stock impact

The new targets sit at $558 and $570, implying potential upside from current levels for some investors. Vertex’s market cap stands at $126,008,312,264, which reflects its large-cap status and pricing power. Short-term stock moves may lag analyst updates, but targets can guide valuation and position sizing for investors.

VRTX analyst rating: Historical analyst coverage and context

Analyst coverage of Vertex has been broadly favorable for years, driven by cystic fibrosis royalties and a growing gene-editing pipeline. Recent moves follow a pattern of steady target revisions as models incorporate clinical and licensing updates. Investors should compare today’s maintained ratings with past revisions to see trend direction and conviction.

VRTX analyst rating: Meyka AI grade and practical next steps

Meyka AI, an AI-powered market analysis platform, rates VRTX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use the grade with the analysts’ maintained ratings to calibrate risk. For trading or long-term buys, check current price levels and company updates on the Meyka VRTX page VRTX on Meyka.

Final Thoughts

The February 13, 2026 updates show two major houses keeping their positive views on Vertex. Scotiabank kept an Outperform and lifted its price target to $558. Morgan Stanley kept an Overweight and raised its target to $570. Both actions are maintenance, not upgrades or downgrades, and indicate steady analyst confidence rather than conviction shifts. For investors the practical takeaway is clear: analysts adjusted valuation models higher, but they left coverage stances unchanged. That combination suggests analysts see more upside in cash flows or pipeline value, while still treating risk as consistent. Weigh the raised targets against Vertex’s $126,008,312,264 market cap and your time horizon. Meyka AI rates VRTX with a grade of B+. This grade is one tool among many and not financial advice. Investors should combine these maintained ratings with earnings data, trial readouts, and personal risk limits before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.